What we are watching
Top 10 by severity and recency
FDA neurology approval pipeline
Anti-amyloid therapy uptake, psychedelic-assisted treatment decisions, and disease-modifying MS regimens are the three active regulatory fronts.
The FDA's accelerated approval pathway for lecanemab (Leqembi) and donanemab (Kisunla) has moved anti-amyloid therapy from pipeline to formulary, but ARIA monitoring requirements and biomarker-driven patient selection are reshaping how payers and health systems make coverage decisions. Separately, FDA's Complete Response Letters for MDMA-assisted therapy and psilocybin studies signal a recalibration of the psychedelic-assisted treatment timeline. On the MS front, Ocrevus Zunovo (subcutaneous) and emerging B-cell depletion strategies are generating SEC disclosure activity across Roche and Biogen. AimwellBio's FDA ingest covers approval letters, label changes, and advisory committee records as they publish.
Monitored issuers and operators
Volume & cadence of public disclosure
GCC & MENA · Neuroscience Infrastructure
Neurological disease burden in the GCC is accelerating — and the institutional infrastructure to address it is being built now.
The Kingdom of Saudi Arabia, UAE, Qatar, and Jordan are investing in dedicated neuroscience centers at an unprecedented rate. King Faisal Specialist Hospital & Research Centre operates one of the region's largest neurosciences departments in Riyadh. Cleveland Clinic Abu Dhabi's Neurological Institute and Hamad Medical Corporation's Neuroscience Institute in Doha are building subspecialty capacity in movement disorders, dementia, and epilepsy. These are not aspirational plans — they are active procurement environments for disease-modifying therapies, diagnostic infrastructure, and real-world evidence partnerships.
Decisions of this scale — formulary placement, center-of-excellence partnership agreements, regulatory pathway consultation, and clinical trial site activation — cannot rest on a single source or vendor pipeline page. They require an adversarial verification layer with origin URLs, fetch timestamps, and reproducible claims for every signal. AimwellBio provides analytical and informational outputs to support these decisions; all intelligence should be reviewed by qualified professionals before action is taken.
Methodology
This report is generated from a live ingest pipeline (tools/scout-ingest). Sources: FDA openFDA, ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, and manufacturer pipeline pages. Signal filter applied: 2026-05-07: post-process filter — explicit neurology/CNS relevance only. Updated —. Every signal carries source URL and fetch timestamp; click any card to view origin.
Confidence framework. Source-backed > pattern-inferred > model-hypothesis > speculative. This report contains source-backed signals only. Pattern-inferred and model-hypothesis tiers are surfaced only inside member dashboards with explicit provenance flags.
Limitations. This is a public, ToS-compliant view. Closed-source manufacturer disclosures, ministry tenders, and private regulatory correspondence are out of scope for this surface. Members access an extended view with partner intelligence subject to NDA.
Mental health scope note. Signals tagged behavioral-health on this surface cover publicly-sourced clinical trial and regulatory activity in psychiatric indications. AimwellBio does not provide clinical guidance, diagnostic interpretation, or patient care recommendations. All analytical outputs are informational only.